Gilead Sciences (NASDAQ:GILD) Q2 2026 Earnings Preview: EPS Decline Expected Amidst Revenue Growth
- Gilead Sciences (NASDAQ:GILD) is projected to report a significant Q2 2026 EPS decline, with Wall Street analysts expecting -$7.26 per share.
- Despite EPS concerns, Gilead Sciences' revenue forecasts are positive, estimated at approximately $7.37 billion, marking a 4% year-over-year increase.
- Analyst sentiment for Gilead Sciences has shifted, with recent downward revisions to both Q2 and full-year 2026 EPS estimates, reflecting evolving profitability expectations.
Gilead Sciences (NASDAQ:GILD) is a leading biopharmaceutical company known for developing medicines for life-threatening diseases. As highlighted by Zacks Equity Research, it is a major drugmaker for HIV and hepatitis C. The company is preparing to release its second-quarter earnings report on August 3rd, 2026, an event closely watched by investors for performance updates.
The main focus for investors is on Gilead Sciences' earnings per share (EPS), which shows a company's profit per outstanding share of stock. Wall Street analysts expect an EPS of -$7.26 for the quarter. Other projections, as highlighted by Zacks Investment Research, estimate a loss of around $7.07 per share, a significant 451.7% decline from the same quarter last year.
Despite the expected loss, revenue forecasts are more positive. Analysts anticipate revenue to be approximately $7.40 billion. More specific estimates from Zacks Investment Research place this figure at $7.37 billion, which would be a 4% increase year-over-year. This growth is expected to be driven by continued strength in the company's HIV franchise.
Analyst sentiment has shifted recently. The consensus EPS estimate saw a 0.4% downward revision over the past 30 days, as highlighted by Zacks Investment Research. Furthermore, the full-year 2026 estimate has been adjusted from an expected profit of $0.08 per share to a loss of $0.78, indicating changing expectations for the company's profitability.
From a valuation standpoint, Gilead Sciences has a trailing price-to-earnings (P/E) ratio of 17.68. This metric compares the company's stock price to its earnings. In terms of financial health, its debt-to-equity ratio is 0.94, which indicates the balance between money owed to creditors and the value owned by shareholders.